Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies

Claudia Trenkwalder, Fabrizio Stocchi, Werner Poewe, Nalina Dronamraju, Chris Kenney, Amy Shah, Florian von Raison, Ana Graf

Research output: Contribution to journalArticle

Abstract

Background: Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia. Methods: Patients were randomized to mavoglurant 100-mg or placebo (4:3) groups (study 1) and mavoglurant 200-mg, mavoglurant 150-mg, or placebo (2:1:1) groups (study 2). Primary outcome was antidyskinetic efficacy, as measured by change from baseline to week 12 in modified Abnormal Involuntary Movement Scale total score. Results: Differences in least-squares mean (standard error) change in modified Abnormal Involuntary Movement Scale total score in week 12 did not reach statistical significance in either study (study 1: mavoglurant 100 mg twice a day versus placebo, 1.7 [1.31]; study 2: mavoglurant 150 mg twice a day (-1.3 [1.16]) and 200 mg twice a day (-0.2 [1.03]) versus placebo). Adverse events incidence was higher with mavoglurant than with placebo. Conclusions: Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment.

Original languageEnglish
Pages (from-to)1054-1058
Number of pages5
JournalMovement Disorders
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • amantadine
  • levodopa-induced dyskinesia
  • mavoglurant
  • mGluR5 antagonist
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies'. Together they form a unique fingerprint.

  • Cite this

    Trenkwalder, C., Stocchi, F., Poewe, W., Dronamraju, N., Kenney, C., Shah, A., von Raison, F., & Graf, A. (2016). Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies. Movement Disorders, 31(7), 1054-1058. https://doi.org/10.1002/mds.26585